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Background: It has been suggested that parkinsonian [Parkinson’s disease (PD)] 
patients might have a “dominant” (DOM) subthalamic nucleus (STN), whose unilateral 
electrical stimulation [deep brain stimulation (DBS)] could lead to an improvement in PD 
symptoms similar to bilateral STN-DBS.
Objectives: Since disability in PD patients is often related to gait problems, in this study, 
we wanted to investigate in a group of patients bilaterally implanted for STN-DBS: (1) if 
it was possible to identify a subgroup of subjects with a dominant STN; (2) in the case, if 
the unilateral stimulation of the dominant STN was capable to improve gait abnormalities, 
as assessed by instrumented multifactorial gait analysis, similarly to what observed with 
bilateral stimulation.
Methods: We studied 10 PD patients with bilateral STN-DBS. A clinical evaluation 
and a kinematic, kinetic, and electromyographic (EMG) analysis of overground walking 
were performed—off medication—in four conditions: without stimulation, with bilateral 
stimulation, with unilateral right or left STN-DBS. Through a hierarchical agglomerative 
cluster analysis based on motor Unified Parkinson’s Disease Rating Scale scores, it was 
possible to separate patients into two groups, based on the presence (six patients, DOM 
group) or absence (four patients, NDOM group) of a dominant STN.
results: In the DOM group, both bilateral and unilateral stimulation of the dominant STN 
significantly increased gait speed, stride length, range of motion of lower limb joints, and 
peaks of moment and power at the ankle joint; moreover, the EMG activation pattern 
of distal leg muscles was improved. The unilateral stimulation of the non-dominant STN 
did not produce any significant effect. In the NDOM group, only bilateral stimulation 
determined a significant improvement of gait parameters.
conclusion: In the DOM group, the effect of unilateral stimulation of the dominant 
STN determined an improvement of gait parameters similar to bilateral stimulation. The 
pre-surgical identification of these patients, if possible, could allow to reduce the surgical 
risks and side effects of DBS adopting a unilateral approach.
Keywords: Parkinson’s disease, deep brain stimulation, dominant subthalamic nucleus, gait, instrumented 
movement analysis, kinematics, kinetics, electromyography
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inTrODUcTiOn
Subthalamic nucleus (STN) deep brain stimulation (DBS) is 
currently a widely performed procedure for the treatment of 
advanced Parkinson’s disease (PD). Bilateral STN-DBS has been 
demonstrated as an effective treatment for advanced PD patients 
both in the short and in the long term, leading to a good control 
of all the PD cardinal symptoms (rigidity, bradykinesia, and 
tremor) and of the drug-induced motor complications (motor 
fluctuations and dyskinesias) (1–7). Moreover, studies performed 
with instrumented movement analysis showed the significant 
improvements provided by bilateral STN-DBS on anticipatory 
postural adjustments before gait initiation (8), kinematics and 
kinetics of lower limb joints during steady-state walking (9), and 
upper limb locomotor synergies (10), that are commonly affected 
in the advanced stage of PD.
Even though bilateral STN-DBS is considered a relatively safe 
procedure, in the last years there has been a growing interest in 
unilateral and staged STN-DBS (i.e., implant of the two electrodes 
during two distinct surgical sittings separated over time), which 
involves lower surgical risk and less post-operative complica-
tions, such as cognitive dysfunctions (11–14). Alberts et al. (13), 
for example, showed a decline in cognitive and motor functions 
when patients were examined under dual-task conditions only 
with bilateral but not with unilateral STN-DBS. In addition, 
several studies demonstrated that also unilateral STN-DBS is 
effective in the control of PD symptoms, with an improvement 
in Unified Parkinson’s Disease Rating Scale (UPDRS) (15) total 
scores ranging from 20 to 40% (16–20). The improvement of 
PD motor symptoms obtained by unilateral STN-DBS is mainly 
observed in the body side contralateral to the stimulated STN; 
nevertheless, several papers also demonstrated a relevant ipsilat-
eral effect of unilateral STN-DBS (21–23). Moreover, the possible 
dominance of right-side motor networks for gait control has been 
hypothesized in a recent paper by Lizarraga et  al. (24), which 
addressed the effects of bilateral, right- or left-side DBS on gait.
Castrioto et al. (25) demonstrated that, in a relevant percentage 
of PD patients treated by bilateral STN-DBS, it was possible to 
identify a so called “dominant STN,” whose unilateral stimulation 
was capable to determine a clinical improvement similar to bilateral 
stimulation. The authors showed the presence of a dominant STN 
in 50% of patients; in about 73% of the cases the dominant STN 
was contralateral to the most affected side of the body, while in the 
others it was ipsilateral. In the dominant-STN group, the percent-
age of improvement of motor UPDRS was 41.7% with bilateral 
STN-DBS and 35.4% with unilateral dominant STN-DBS, while 
in the non-dominant STN group a significant improvement in the 
motor UPDRS score was found only with bilateral stimulation. 
This finding has increased the interest of unilateral STN-DBS as a 
possible alternative approach to bilateral DBS in some PD patients.
In the perspective to identify PD patients with a dominant 
STN before surgery, the authors suggested the need of further 
studies (25).
Gait disorders play an outstanding role in PD, becoming with 
the progression of disease one of the major source of disability 
(26–28). Unfortunately, the ability to detect gait changes through 
the UPDRS gait item is limited.
On the basis of these considerations, the aim of the present work 
was to investigate in a group of PD patients bilaterally implanted 
for STN-DBS: (1) if it was possible to identify a subgroup of 
patients with a dominant STN with the method indicated by 
Castrioto et al.; (2) in the case, if the unilateral stimulation of the 
dominant STN was capable to improve gait anomalies similarly 
to what observed with bilateral stimulation, using a kinematic, 
kinetic, and electromyographic (EMG) analysis of overground 
walking.
MaTerials anD MeThODs
subjects
Ten patients with idiopathic PD, bilaterally implanted in the STN 
as described in Lopiano et al. (29), and 10 age-matched healthy 
controls (5 males, 5 females; mean ± SD age 61.4 ± 5.0; age range 
55–69 years) voluntarily took part in the study. The main charac-
teristics of PD patients were the following: five males, five females; 
age (mean ± SD): 60.2 ± 4.8 years (range 52–68 years); PD duration: 
16.9 ± 5.5 years; time postsurgery: 10.4 ± 7.0 months; and Hoehn 
and Yahr stage in medication off: 3.7 ± 0.7. The inclusion criteria 
for surgery had been a diagnosis of idiopathic PD with severe 
motor fluctuation or dyskinesias, a good response to levodopa 
challenge (UPDRS motor score improvement ≥30%), the absence 
of relevant cognitive or psychiatric disturbances and the absence 
of significant abnormalities at the brain imaging (MRI). The mean 
levodopa dosage at the time of the study was 112.5 ± 186.1 mg/day 
(range 0–500 mg/day), and the mean levodopa equivalent dosage 
was 274.5 ± 303.5 mg/day (range 0–950 mg/day); three patients 
were without antiparkinsonian drugs.
All patients were evaluated preoperatively by the UPDRS III 
(motor section) in the off condition (overnight withdrawal of all 
antiparkinsonian drugs) and in the on condition (about 60 min 
after the administration of a levodopa dose 25% higher of the 
first morning dose). UPDRS IV (complications of therapy) was 
also administered.
After surgery, the position of the active contacts of the elec-
trodes was calculated as described in a previous paper (30).
All subjects gave their written informed consent to the experi-
mental protocol, which conformed to the Declaration of Helsinki 
and was approved by the Ethics Committee of CTO Hospital 
(Turin).
experimental Protocol
After a 12-h washout of all antiparkinsonian drugs, patients 
performed four sets of walking trials in the following conditions: 
(1) bilateral STN stimulation (BIL); (2) right STN stimulation 
(UNI_R); (3) left STN stimulation (UNI_L); (4) stimulation off 
(OFF). BIL was the chronic condition of the patients as they arrived 
to the lab and it was always tested first to minimize the duration of 
the whole session by avoiding initial and posttrial washout phases. 
After the assessment under BIL stimulation, conditions UNI_R, 
UNI_L and OFF were randomized among patients. Patients were 
always unaware of the current condition. After each change of 
stimulation parameters there was a resting time of at least 60 min, 
which was considered enough for DBS washout (31).
FigUre 1 | Dendrogram representing the subgroups of Parkinson’s disease 
subjects derived from the cluster analysis.
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For each condition, subjects performed eight walking trials at 
their preferred speed along a 10 m path. Subjects with PD were 
evaluated by the UPDRS motor section (part III) before each gait 
session; the sub-scores for tremor (items 20, 21), rigidity (item 
22), akinesia (items 23, 24, 25, 26, and 31), gait (item 29), postural 
stability (item 30), and the separate scores for right and left sides 
of the body were also calculated.
The duration of the entire experimental procedure, including 
subjects’ preparation, instrumental gait sessions, clinical assess-
ments, and resting periods, was about 5 h and a half.
Non-disabled controls underwent only one gait analysis ses-
sion consisting of eight walking trials at self-selected speed.
setup
Kinematics of body segments were measured during walking, using 
an optoelectronic system (ELITE, BTS, Milan, Italy—four cameras, 
sampling frequency 50 Hz), which computed the 3D coordinates 
of spherical markers (10 mm diameter) fixed on the following bony 
landmarks: sacrum, posterior superior iliac spines, lateral femoral 
condyles, lateral malleoli, and fifth metatarsal heads of both sides 
of the body. Ground reaction forces were acquired at a sampling 
frequency of 50 Hz with a dynamometric platform (Kistler, GmbH, 
Winterthur, Switzerland). Surface EMG signals were recorded 
using a telemetric 8-channel system (TELEMG, BTS, Milan, 
Italy) from tibialis anterior (TA), gastrocnemius medialis (GAM), 
rectus femoris (RF), and semimembranosus (SM) muscles of both 
legs. Myoelectric signals were collected by preamplified Ag/AgCl 
electrodes (diameter: 25 mm, bipolar configuration, interelectrode 
distance: 20 mm), band-pass filtered (between 10 and 200 Hz), and 
acquired at a sampling frequency of 500 Hz.
Data Processing
Markers’ coordinates and ground reactions were processed to 
produce hip, knee and ankle joint angles, moments, and power 
in the sagittal plane. The time course of all kinematic and kinetic 
variables were time normalized as a percentage of the stride dura-
tion (between two consecutive heel strike of the same foot), and 
for each cycle the following variables were computed: spatiotem-
poral gait parameters (walking velocity, cadence, stride length, 
and stance phase duration), range of motion (ROM) and moment 
and power peak of hip, knee, and ankle joints. EMG signals were 
high-pass filtered at 50  Hz (fourth order zero-lag Butterworth 
filter) to remove movement artifacts and then they were rectified 
and low-pass filtered at 7.5 Hz to obtain linear envelopes (32). 
All EMG profiles were normalized in time as a percentage of the 
stride duration. Finally, to quantify the level of motor output, 
the root mean square (RMS) of each envelope EMG signal was 
computed over functionally relevant stride periods, in particular: 
first double stance for TA and RF, push-off phase for GAM, early 
swing for TA and late swing for SM. No amplitude normalization 
was applied since RMS values were compared within subjects 
among the four STN stimulation conditions, without removal 
and replacement of the electrodes.
statistical analysis
A hierarchical agglomerative cluster analysis was performed, 
following the method used by Castrioto et al. (25), to determine 
whether the motor UPDRS score from different stimulation 
conditions supported the existence of a group of PD subjects with 
a dominant STN. In particular, based on the effects of unilateral 
stimulation on clinical motor scores, it was possible to identify 
for each subject the most effective (UNIbest) and the least effective 
(UNIworst) side of stimulation. Subsequently, six ratios between 
scores related to different stimulation conditions were computed: 
UNIbest/BIL, UNIworst/BIL, OFF/BIL, UNIworst/UNIbest, UNIbest/OFF, 
UNIworst/OFF. The cluster analysis was performed on these six 
variables using the correlation distance measure and the McQuitty 
(Weighted Pair Group Method with Arithmetic Mean) agglomera-
tion method. On the basis of the results of this analysis, PD subjects 
were subsequently pooled into two groups, according to the pres-
ence (DOM group) or not (NDOM group) of a dominant STN.
Considering the small sample size, data were analyzed using 
non-parametric tests. Differences among stimulation conditions 
were analyzed using Friedman test and Tukey–Kramer post hoc 
test. Differences in UPDRS III scores and gait analysis variables 
between stimulation sides and body sides were evaluated by 
Wilcoxon matched pairs test (Wt). The same test was used for 
the comparison of stimulation parameters and position of the 
electrodes between right and left side. Comparisons between 
DOM and NDOM groups and between each PD group and 
controls were performed using Mann–Whitney U test (MWt). 
Level of significance was set to 0.05.
resUlTs
cluster analysis
Three clusters were identified (Figure  1). The first cluster 
included one subject (S1). In this patient, right STN stimulation 
alone achieved an improvement of UPDRS III score equal to that 
obtained with bilateral STN stimulation and 50% greater than 
that obtained with left stimulation.
The second cluster included five subjects (S3, S4, S6, S8, and 
S10) where the unilateral stimulation of one side (right side for 
TaBle 1 | Demographic clinical characteristics (median and range) for 
Parkinson’s disease (PD) subjects with a dominant subthalamic nucleus (STN) 
(DOM) and PD subjects without a dominant STN (NDOM).
DOM  
(n = 6)
nDOM  
(n = 4)
p 
(MWt)
Age (years) 59.0 (52.0–68.0) 61.0 (57.0–66.0) 0.593
Gender (no. male/no. female) 2/4 3/1
Disease duration (years) 21.0 (13.0–22.0) 13.5 (8.0–17.0) 0.085
Time from surgery (months) 11.0 (8.0–28.0) 8.0 (4.0–9.0) 0.234
H&Y stage (medication and 
stimulation off) 
4.0 (2.5–4.5) 3.5 (3.0–4.0) 0.581
Presurgery (medication off)
UPDRS III Motor Examination 62.0 (46.0–95.0) 57.8 (44.5–73.0) 0.522
Tremor (items 20, 21) 6.5 (2.0–22.5) 9.8 (4.0–17.0) 0.394
Rigidity (item 22) 12.8 (10.5–19.5) 12.8 (8.0–17.5) 0.522
Akinesia (items 23, 24, 25, 26, 31) 26.8 (21.0–32.0) 23.8 (21.0–26.0) 0.278
Postural stability (item 30) 2.5 (2.0–4.0) 2.0 (1.0–2.0) 0.040
Gait (item 29) 2.5 (2.0–4.0) 2.0 (1.0–2.0) 0.040
Asymmetry of symptomsa 3.8 (1.1–11.9) 5.7 (2.7–9.3) 0.286
Presurgery (medication on)
UPDRS III Motor Examination 21.0 (10.0–36.5) 21.3 (5.5–22.0) 0.522
Tremor (items 20, 21) 0.0 (0.0–1.0) 0.5 (0.0–2.0) 0.456
Rigidity (item 22) 5.0 (2.0–8.5) 5.3 (0.0–7.5) 0.831
Akinesia (items 23, 24, 25, 26, 31) 8.5 (1.0–17.0) 8.0 (2.0–9.0) 0.594
Postural stability (item 30) 1.8 (1.0–3.0) 1.5 (1.0–2.0) 0.594
Gait (item 29) 0.8 (0.0–3.0) 0.5 (0.5–0.5) 0.394
Asymmetry of symptomsa 5.8 (1.4–36.4) 4.5 (0.0–19.5) 0.640
Presurgery (complications of therapy)
UPDRS IV (items 32, 33, 39) 6.3 (4.0–7.0) 3.0 (3.0–4.0) 0.014
aAsymmetry of symptoms: % [UPDRS (worst side) − UPDRS (best side)]/total  
UPDRS III.
UPDRS, Unified Parkinson’s Disease Rating Scale; H&Y, Hoehn and Yahr stage; MWt, 
Mann–Whitney U test.
Significant differences between DOM and NDOM group (p < 0.05) are reported in bold.
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S3, S4, and S8; left side for S6 and S10) induced a mean motor 
improvement 11% higher than that obtained stimulating the other 
side and 16% smaller than that achieved by bilateral stimulation.
The third cluster included four patients (S2, S5, S7, and S9) 
where unilateral right and left stimulation produced similar mean 
improvements (mean difference 2%), 30% smaller than those 
generated by bilateral stimulation.
In summary, 6 of the 10 tested patients (DOM group, 60%) 
showed the presence of a dominant STN, whose stimulation 
produced motor improvements equal or slightly inferior to 
bilateral stimulation. Four of these subjects demonstrated right 
dominance, whereas two patients showed left dominance. In 
one subject (S10), the dominant STN was ipsilateral to the most 
affected side. Conversely, 4 of the 10 tested subjects (NDOM 
group, 40%) did not show the presence of a dominant STN and 
obtained greater improvements upon bilateral stimulation.
Dominant-sTn group versus  
non-Dominant sTn group
Presurgical Evaluations
As reported in Table  1, the dominant-STN (DOM) and the 
non-dominant STN (NDOM) groups showed similar demo-
graphic characteristics, even though there was a trend toward 
a longer disease duration for the DOM group (pMWt =  0.085). 
The disease severity was similar in the two groups, except 
for a significantly lower postural stability (pMWt =  0.040) and 
poorer gait function (pMWt =  0.040) of the DOM group in the 
medication-off condition, as indicated by the specific UPDRS 
items. Moreover, in medication-on condition, the DOM group 
demonstrated more therapy-related complications than NDOM 
group (pMWt = 0.014).
Effects of STN Stimulation on Clinical Motor 
Symptoms
Results related to motor UPDRS III are reported in Table 2 (A).
DOM and NDOM groups showed comparable UPDRS III 
scores in basal (OFF) condition (pMWt > 0.324) and under bilateral 
STN stimulation (pMWt > 0.114). In the DOM group, both bilateral 
STN stimulation (BIL) and unilateral stimulation of the dominant 
side (UNI_D) induced statistically significant improvements of 
UPDRS III total score and sub-scores related to tremor, rigidity, 
and akinesia, whereas unilateral stimulation of the non-dominant 
STN (UNI_ND) did not produce significant ameliorations with 
respect to basal condition (OFF). Postural stability and gait sub-
scores, instead, appeared significantly improved only upon BIL. 
Moreover, as shown in Table  3, UNI_D induced a statistically 
significant improvement in the motor UPDRS sub-scores of 
both ipsilateral (Δ% = median percentage improvement = 34.2) 
and contralateral side(Δ% = 80.1), while UNI_ND significantly 
reduced contralateral (Δ% = 54.6) but not ipsilateral symptoms 
(Δ% = 7.9).
By contrast, in the NDOM group only bilateral stimulation 
significantly improved motor UPDRS score and sub-scores (see 
Table 2, A), while unilateral stimulation of right (UNI_R) and left 
(UNI_L) STN reduced PD motor symptoms in a similar manner, 
but not significantly. Moreover, as shown in Table 3, unilateral 
stimulation significantly improved contralateral motor symptoms 
(UNI_R: Δ% = 42.3; UNI_L: Δ% = 60.2) but not ipsilateral scores 
(UNI_R: Δ% = 11.8; UNI_L: Δ% = 1.0).
Effects of STN Stimulation on Gait
Table  2 (B–E) summarized the results emerged from the gait 
analysis in the four STN stimulation conditions.
In OFF condition, both DOM and NDOM patients showed 
similar gait characteristics. In particular, both PD groups adopted 
statistically significant lower velocity, shorter stride length and 
longer stance time, with respect to healthy control subjects 
(Table 2, B). Both groups showed lower ROM of hip, knee and 
ankle joints (Table  2, C; Figure  2), while only DOM group 
demonstrated statistically significant alterations of gait kinetics, 
in particular lower moment peak at the ankle and lower power 
peak at the hip and ankle joints (Table 2, D; Figure 2). Visual 
analysis of EMG signals revealed consistent anomalies in the 
activation pattern of tested muscles in both DOM and NDOM 
groups with respect to healthy controls (see Figures 3A–C). In 
particular, PD patients showed: (i) a reduced or absent activity 
of RF during first double stance, (ii) anticipated and reduced or 
absent activation peak of GAM during push-off phase, and (iii) a 
reduced activity of TA during early swing and, at a larger extent, 
during first double stance.
TaBle 2 | Median (range) values of postsurgery clinical characteristics (A) and quantitative gait parameters (B–E) for Parkinson’s disease (PD) patients with dominant subthalamic nucleus (STN) (DOM) and PD patients 
without dominant STN (NDOM) in the different conditions.
control (n = 10) DOM (n = 6) nDOM (n = 4)
OFF(a) Uni_nD(b) Uni_D(c) Bil(d) OFF(a) Uni_r(b) Uni_l(c) Bil(d)
a. clinical variables
UPDRS III total 60.8(c,d) (42.0–80.5) 39.5(d) (21.0–51.5) 26.8(a) (17.5–39.0) 16.3(a,b) (7.5–29.0) 62.5(d) (60.5–72.0) 47.0 (36.0–54.0) 47.5 (34.5–53.0) 28.3(a) (10.5–36.5)
Tremor (items 20, 21) 4.5(c,d) (1.5–13.0) 3.8 (0.0–9.5) 0.8(a) (0.0–7.5) 0.3(a) (0.0–3.5) 10.5(d) (1.0–19.0) 5.8 (0.5–11.0) 6.8 (0.0–10.0) 2.0(a) (0.0–5.5)
Rigidity (item 22) 15.5(c,d) (11.0–19.0) 10.5 (6.5–15.0) 8.0(a) (5.0–10.5) 5.0(a) (2.0–7.5) 13.0(d) (11.5–18.0) 10.3 (8.0–11.0) 11.5 (6.5–13.5) 7.8(a) (2.0–9.5)
Akinesia (items 23,  
24, 25, 26, 31)
25.5(c,d) (15.0–31.0) 17.5 (3.5–21.0) 9.0(a) (5.5–15.5) 4.0(a) (2.0–12.0) 28.3(d) (25.5–31.5) 21.5 (21.0–22.0) 20.0 (18.0–24.0) 11.3(a) (6.5–14.0)
Postural stability  
(item 30)
2.0(d) (1.5–3.0) 2.0 (1.0–2.0) 1.8 (1.0–2.0) 1.5(a) (1.0–2.0) 1.8(d) (1.0–3.0) 1.5 (0.5–2.0) 1.5 (0.5–2.0) 1.0(a) (0.5–2.0)
Gait (item 29) 2.5(d) (1.5–3.5) 1.5 (0.0–2.5) 1.3 (0.0–2.5) 0.5(a) (0.0–1.0) 2.0(d) (1.0–3.5) 1.5 (1.0–3.0) 1.3 (1.0–3.0) 0.8(a) (0.0–1.5)
B. spatiotemporal gait variables
Velocity  
(% body height/s)
65.0 (45.8–86.3) *30.3(c,d) (11.3–41.5) 40.3 (28.1–65.1) 53.4(a) (10.1–31.5) 54.2(a) (39.1–67.8) *35.7(d) (21.6–57.9) 38.2 (26.8–67.7) 44.0 (27.4–66.9) 49.5(a) (29.9–67.8)
Stride length  
(% body height)
74.1 (57.8–88.5) *33.4(c,d) (11.0–45.4) 40.6(d) (27.1–64.7) 56.5(a) (32.5–68.5) 62.2(a,b) (46.5–73.5) *48.0(d) (33.0–57.9) 52.9 (42.3–66.6) 54.3 (43.4–65.2) 57.7(a) (46.0–69.8)
Cadence (stride/min) 54.9 (47.5–60.5) 55.5 (38.5–61.8) 60.4 (48.0–77.6) 53.8 (40.4–64.5) 55.4 (43.4–61.1) 44.0 (38.9–60.09) 43.5 (36.7–61.0) 48.2 (37.8–61.6) 49.7 (39.0–60.7)
Stance time  
(% stride)
59.4 (55.5–62.3) *64.9 (59.2–71.5) 62.7 (57.0–64.2) 59.5 (58.3–67.0) 60.2 (58.3–63.4) *64.8 (59.4–68.9) 63.3 (58.6–68.3) 62.2 (59.2–68.5) 61.9 (58.8–70.3)
c. Kinematic gait variables
Hip range of motion  
(ROM) (°)
50.8 (40.5–65.4) *26.4(c,d) (18.9–35.6) 31.0(d) (20.1–43.7) 40.2(a) (23.6–47.5) 44.8(a,b) (32.9–52.1) *33.7 (23.5–41.5) 39.9 (30.3–49.3) 37.2 (32.2–43.6) 42.9 (29.1–47.3)
Knee ROM (°) 59.2 (56.4–67.6) *36.7(c,d) (23.6–45.5) 44.8 (28.4–51.2) 48.9(a) (26.9–61.4) 51.6(a) (43.1–60.9) *41.5 (29.8–51.2) 45.2 (33.7–61.8) 45.3 (37.7–52.1) 45.9 (38.3–54.9)
Ankle ROM (°) 26.1 (20.3–34.5) *13.4(c,d) (8.7–18.6) 16.1(d) (14.4–20.0) 20.7(a) (15.7–22.1) 22.5(a,b) (19.8–23.7) *16.7 (13.6–18.7) 18.4 (17.2–21.8) 18.1 (16.6–21.0) 17.9 (15.2–18.1)
D. Kinetic gait variables
Hip moment  
peak (Nm/kg)
1.07 (0.63–1.60) 0.93 (0.59–1.26) 0.90 (0.53–1.41) 1.09 (0.50–1.38) 1.21 (0.63–1.37) 1.23 (0.61–1.52) 1.22 (1.07–1.48) 1.22 (0.62–1.42) 1.09 (0.59–1.45)
Knee moment  
peak (Nm/kg)
0.40 (0.16–0.85) 0.33(d) (0.16–0.44) 0.41 (0.24–0.51) 0.45 (0.37–0.70) 0.59(a) (0.18–0.81) 0.40 (0.12–0.70) 0.31 (0.23–0.80) 0.32 (0.24–0.85) 0.33 (0.30–0.46)
Ankle moment  
peak (Nm/kg)
1.52 (1.31–1.65) *0.99(c,d) (0.97–1.29) 1.16 (0.83–1.31) 1.25(a) (1.07–1.31) 1.27(a) (0.99–1.39) 1.34 (1.03–1.45) 1.22 (0.96–1.54) 1.20 (0.91–1.52) 1.29 (0.91–1.59)
Hip power  
peak (W/kg)
2.06 (0.93–2.67) *0.78 (0.37–1.66) 1.15 (0.42–1.89) 1.84 (0.50–2.54) 1.92 (0.52–2.30) 1.32 (0.71–1.87) 1.55 (1.28–3.00) 1.51 (0.94–2.65) 1.21 (1.03–2.79)
Knee power  
peak (W/kg)
0.30 (0.13–0.93) 0.24 (0.07–0.45) 0.20 (0.11–0.49) 0.29 (0.09–0.75) 0.32 (0.23–0.90) 0.08 (0.07–0.53) 0.20 (0.06–0.98) 0.18 (0.06–0.84) 0.28 (0.06–0.34)
Ankle power  
peak (W/kg)
3.06 (1.63–4.59) *0.86(c,d) (0.47–1.60) 1.29 (0.80–2.98) 1.89(a) (0.84–2.86) 2.03(a) (1.25–3.05) 1.27 (0.69–4.81) 1.72 (0.57–3.02) 1.68 (0.60–4.64) 2.03 (0.70–2.48)
e. electromyographic root mean square
Semimembranosus  
(late swing) (μV)
23.7 (8.3–64.6) 19.1 (10.4–47.8) 23.2 (14.3–88.3) 24.6 (11.9–72.4) 26.4 (9.6–67.1) 22.0 (10.0–51.5) 21.2 (9.2–82.9) 24.6 (15.6–68.6) 31.2 (15.2–78.8)
Rectus femoris (first 
double stance) (μV)
25.1 (13.5–64.2) *19.2 (10.4–30.6) 19.7 (11.9–66.2) 30.4 (9.2–59.4) 31.6 (11.8–60.3) *14.3 (6.4–47.6) 15.2 (10.2–47.7) 25.1 (13.4–62.3) 28.4 (11.6–80.3)
Gastrocnemius  
medialis (push–off) 
(μV)
124.3 (36.0–232.0) *33.5(c,d) (6.2–88.0) 42.5(d) (14.5–106.9) 47.4(a) (12.0–148.4) 59.5(a,b) (17.5–186.1) *35.0(b,d) (21.9–88.8) 47.7(a) (30.1–97.1) 39.8 (17.5–93.8) 47.3(a) (31.1–105.5)
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In the DOM group, both BIL and UNI_D stimulation sig-
nificantly increased, to a similar extent, gait speed, stride length 
(Table  2, B), the angular displacements (ROM) of the three 
main lower limb joints (Table 2, C; Figure 2A) and the peaks of 
moment and power at the ankle joint (Table 2, D; Figure 2A). 
Conversely, no statistically significant differences between OFF 
and UNI_ND conditions were noticed in any aforementioned 
variables (Table 2, B–D; Figure 2A). With reference to muscles 
activity, both BIL and UNI_D similarly improved the EMG 
activation pattern of distal and, to a lower extent, of proximal leg 
muscles (Table 2, E). In particular (see also Figure 3B), upon BIL 
and UNI_D, the activation burst of TA typically present around 
ground contact, at the beginning of the first double stance, was 
restored, GAM muscle increased its EMG activity during push-
off, while RF and SM recovered their activation burst during 
first double support and late swing, respectively. Conversely, no 
significant improvements were noticed in UNI_ND condition 
(Table 2, E; Figure 3B).
In the NDOM group (Table  2, B), unilateral and bilateral 
stimulation slightly increased gait speed and stride length, but 
a statistically significant improvement was noticed only upon 
BIL. Kinematic and kinetic variables were almost unaltered by 
STN stimulation, even though a trend toward an increase of hip 
angular displacement and ankle power peak was present (Table 2, 
C,D). Moreover, a shift of the kinematic and kinetic profiles 
toward normal templates was noticed for the three considered 
joints (Figure 2B). This trend was more pronounced upon bilat-
eral than unilateral stimulation. Bilateral stimulation significantly 
increased the EMG activity of TA during the first double stance 
and GAM at push-off. In addition, a trend toward improved 
activation was noticed in RF during first double support and 
in SM during late swing, although non-statistically significant 
(Table 2, E; Figure 3C). Unilateral right and left stimulation did 
not generate significant improvements (Table 2, E; Figure 3C).
In both DOM and NDOM group, none of the aforementioned 
variables showed the significant asymmetries between ipsilateral 
and contralateral sides that emerged from clinical assessment.
Location of the Active Contacts and Stimulation 
Parameters
As shown in Table 4, no differences were found between DOM 
and NDOM groups in either the location of the active contacts or 
the electric parameters of stimulation.
Moreover, no statistically significant differences were found 
in the electrodes location and stimulation parameters between 
the dominant and non-dominant side of stimulation for DOM 
group, and between right and left stimulation sides for NDOM 
group (Table 4).
DiscUssiOn
In our study, we used the method described by Castrioto et al. 
(25) to verify if, in a group of PD patients treated with bilateral 
STN-DBS, it was possible to identify a subgroup who presented 
the dominance of one STN, and to quantitatively assess the effect 
of the unilateral stimulation of the dominant STN using a kin-
ematic, kinetic and EMG analysis of overground walking.Ta
B
le
 2
 | 
C
on
tin
ue
d
TaBle 3 | Motor Unified Parkinson’s Disease Rating Scale scores (median and range) related to the side of the body ipsilateral and contralateral to the different 
unilateral subthalamic nucleus (STN) stimulation conditions for the group with a dominant STN (DOM) and the group without a dominant STN (NDOM).
OFF Uni_D Δ% OFF Uni_nD Δ%
DOM 
(n = 6)
Ipsilateral body side 15.5 (12.5–29.0) 9.3 (5.5–18.5) 34.2* (26.8–64.5) 21.8 (14.0–24.0) 17.0 (7.5–23.5) 7.9 (0.0–63.4)
Contralateral body side 21.8 (14.0–24.0) 4.0 (3.0–9.0) 80.1* (35.7–85.4) 15.5 (12.5–29.0) 8.3 (3.5–11.5) 54.6* (39.3–77.4)
OFF Uni_r Δ% OFF Uni_l Δ%
NDOM 
(n = 4)
Ipsilateral body side 21.5 (18.5–22.0) 19.0 (13.5–23.0) 11.8 (−4.5 to 27.0) 24.0 (20.5–28.5) 25.3 (19.5–28.5) 1.0 (−13.0 to 4.9)
Contralateral body side 24.0 (20.5–28.5) 13.5 (13.0–17.0) 42.3* (26.1–50.9) 21.5 (18.5–22.0) 8.8 (1.0–13.0) 60.2* (38.1–94.6)
Δ%, percentage improvement with respect to basal (OFF) condition; OFF, basal condition (medication off-bilateral stimulation off); UNI_D, unilateral stimulation of dominant STN; 
UNI_ND, unilateral stimulation of non-dominant STN; UNI_R, unilateral stimulation of right STN; UNI_L, unilateral stimulation of left STN.
Symbol “*” indicates statistically significant difference (p < 0.05) between OFF condition and a specific unilateral stimulation condition.
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Indeed, the effects of unilateral STN-DBS on gait are not fully 
understood (33). While both improvements and worsening of gait 
performances were reported at individual level in medication-
on condition (34, 35), in medication-off condition significant 
improvements induced by unilateral STN stimulation have 
been documented in gait initiation (8) and steady-state walking 
(16–18, 21, 36–39). Most of these studies analyzed gait improve-
ment through UPDRS gait item (16, 17, 39) or spatiotemporal 
parameters (16, 18, 21, 36, 39). Only three studies analyzed the 
effect of unilateral stimulation on more specific aspects of gait, 
such as spatiotemporal parameters (24), lower limb joints kin-
ematics (37) and EMG activity of leg muscles (38). In one of these 
studies it was also hypothesized a dominant role of the right side 
motor network for gait control (24). To the best of our knowledge, 
no study related to multifactorial analysis of gait which combines 
kinematics, kinetics and EMG data has been performed so far for 
a complete evaluation of the effects of unilateral stimulation of 
dominant and non-dominant STN.
In our study, we found that 60% of patients (6/10) showed a 
dominant STN, whose stimulation determined a 55.9% improve-
ment in motor UPDRS score with respect to the off stimulation 
condition, slightly (but not statistically) inferior to what observed 
with bilateral STN stimulation. In one patient the dominant STN 
was ipsilateral to the most affected body side. Moreover, the 
motor improvement due to the dominant STN stimulation was 
significant both on the contralateral and on the ipsilateral body 
side. By contrast, the unilateral stimulation of the non-dominant 
STN did not provide any statistically significant improvements in 
motor UPDRS score and sub-scores, despite the similar location 
of the active contacts and the comparable electric stimulation 
parameters. These findings, in turn, confirm those obtained by 
Castrioto et  al. (25) and seem to support the existence of the 
“dominant-STN phenomenon” in a subgroup of PD subjects.
By contrasts, it was not possible to detect a significant 
improvement on clinical gait score, as measured by UPDRS item 
29, for dominant-STN stimulation, probably for the small sample 
size and for the relative poor sensibility of the UPDRS gait score. 
These limitations are partly overcome by the multifactorial gait 
analysis performed in this study, which instead revealed sig-
nificant ameliorations of walking provided by the dominant-STN 
stimulation. In particular, the analysis of the spatiotemporal gait 
variables demonstrated that both bilateral and unilateral stimula-
tion of the dominant STN significantly increased gait speed and 
stride length, while no significant changes were observed in 
cadence. This is an interesting result which suggests that, similarly 
to bilateral STN-DBS, also unilateral DBS of the dominant STN 
can improve walking velocity by increasing stride length, typi-
cally shortened in PD (40), but not cadence, whose control has 
been demonstrated to be intact in these subjects (41). The effect 
of unilateral STN stimulation on stride length was analyzed also 
by Lizarraga et al. (24), who found that right-sided stimulation 
provided an improvement similar to bilateral stimulation and 
significantly higher than left-sided stimulation. This finding is in 
accordance with the present results, which show that four out of 
six DOM patients of our sample have a dominant right STN.
The angular displacements of the three main lower limb joints 
and the peaks of moment and power at the ankle joint were also 
similarly increased by both bilateral and unilateral dominant-STN 
stimulation. Finally, the EMG activation pattern, mainly of distal 
muscles, was improved by both these stimulation modalities. By 
contrast, the unilateral stimulation of the non-dominant STN in 
the DOM group and the unilateral stimulation of right or left STN 
in the NDOM group, failed to reveal a significant effect on the 
above reported gait parameters compared with OFF condition.
Analyzing the effect of unilateral STN stimulation on all gait 
variables, we did not observe any significant difference between the 
ipsilateral and contralateral body side, contrarily to what was found 
for motor UPDRS score; this could indicate that the gait improve-
ment observed with the unilateral stimulation of the dominant 
STN is probably due to a bilateral effect on the locomotor system.
The anatomical explanation for the bilateral effect of unilateral 
STN stimulation could be the presence of several cross-connections 
between the basal ganglia and the cortical areas (42, 43) and between 
the basal ganglia and the peduncolopontine nucleus (PPN), com-
ponent of the mesencephalic locomotor reticular region (44, 45).
Subthalamic nucleus receives inhibitory inputs from the 
ipsi- and contralateral external globus pallidus (GPe) (46) and 
excitatory inputs from the ipsilateral premotor and motor cortex 
(47) and from the ipsi- and contralateral parafascicular nucleus 
of the thalamus (Pf-Th) (46, 48). Furthermore, it projects itself 
excitatory inputs to the Pf-Th (46).
The interconnection of the two STN is demonstrated by the 
recording of an increase in contralateral STN neuronal activity 
for the unilateral STN stimulation (49, 50). Moreover, unilateral 
STN stimulation seems also capable to determine changes in 
bursting an oscillatory activity of contralateral STN neurons, in 
relation for example to the presence or absence of stimulation-
induced dyskinesias (51).
FigUre 2 | Kinematic and kinetic profiles (within-subject mean curves) from representative Parkinson’s disease subjects with dominant subthalamic nucleus (STN) 
(a) and without dominant STN (B) in the different STN stimulation conditions. From panels (a), note that unilateral stimulation of the dominant STN (UNI_D) improves 
all profiles more than UNI_ND and similarly to bilateral stimulation (BIL). From panels (B), note that unilateral stimulation of right (UNI_R) and left STN (UNI_L) produce 
similar improvement lower than that generated by bilateral simulation (BIL).
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The existence of bilateral connections of basal ganglia 
nuclei is also demonstrated by the observation that unilateral 
STN-DBS produces bilateral cerebral blood flow responses 
(rCBF) in cortical and cerebellar regions (52–54), and that 
these rCBF changes do not differ for ipsi- or contralateral STN 
stimulation (54).
FigUre 3 | (a) Electromyographic (EMG) linear envelopes for control subjects. Intersubject mean curve (dashed line) ± SD band (bold lines). Amplitude is 
normalized to 95th percentile of control group. (B,c) Representative examples of EMG linear envelopes (within-subject mean) from Parkinson’s disease patients with 
dominant subthalamic nucleus (STN) (B) and without dominant STN (c) in the different conditions.
TaBle 4 | Comparison of the location of the active contacts and of the stimulation parameters between patients with dominant (DOM) and without dominant (NDOM) 
subthalamic nucleus (STN), between the dominant (D_STN) and the not-dominant (ND_STN) STN in the DOM group and between the right (R_STN) and the left (L_STN) 
STN in the NDOM group.
DOM group 
(n = 6)
nDOM group 
(n = 4)
p-Value DOM D_sTn DOM nD_sTn p-Value nDOM r_sTn nDOM l_sTn p-Value
active contacts positiona
Lateral (mm) 11.8 ± 0.6 11.6 ± 0.7 1.000 12.0 ± 0.0 11.5 ± 0.8 0.157 11.6 ± 0.8 11.6 ± 0.8 1.000
Antero-posterior (mm) −1.3 ± 0.9 −1.7 ± 0.9 0.172 −0.9 ± 1.0 −1.7 ± 0.7 0.078 −1.1 ± 1.0 −2.2 ± 0.4 0.141
Vertical (mm) −1.3 ± 1.3 −2.1 ± 1.3 0.291 −1.0 ± 1.7 −1.6 ± 0.7 0.500 −1.6 ± 1.4 −2.6 ± 1.2 0.273
Parameters of stimulation
Voltage (V) 3.1 ± 0.3 3.1 ± 0.5 0.944 3.1 ± 0.3 3.2 ± 0.3 0.655 3.1 ± 0.6 3.1 ± 0.5 0.655
Pulse width (μs) 67.5 ± 13.6 78.8 ± 15.6 0.257 70.0 ± 15.5 65.0 ± 12.2 0.317 82.5 ± 15.0 75.0 ± 17.3 0.317
Frequency (Hz) 144.2 ± 19.3 141.9 ± 15.3 0.273 145.8 ± 22.2 142.5 ± 17.8 0.524 143.8 ± 18.9 140.0 ± 13.5 0.461
aLocation of the active contacts in relation to the midcommissural point.
D_STN, dominant STN; ND_STN, non dominant STN; R_STN, right STN; L_STN, left STN.
Values are mean ± SD.
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Moreover, recently some authors demonstrated the presence 
of an interhemispheric functional connectivity studying the STN-
Local Field Potential coherence (55–58).
The effects of STN-DBS on gait are likely to be related to the 
interconnection between the STN and the PPN (59). Recently, 
Neagu et al. (60) demonstrated the presence of ipsilateral PPN 
long latency polyphasic potentials (40–45 ms) in patients unilat-
erally stimulated in the STN. They argued that these potentials 
could be the result of the activation of fibers or other structures 
near the PPN, probably through a polysynaptic pathway on the 
10
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basis of their long latency. This pathway could be represented by 
ipsilateral projections from internal globus pallidus (GPi) to PPN 
(61) or most likely by connections between the precentral and 
premotor cortex, the red nucleus and the PPN (62, 63).
Furthermore, the recent advent of directional leads capable 
to focus the stimulation field in a specific horizontal direction 
(64), combined with instrumented gait analysis method, might 
provide insights on the role of specific basal ganglia regions in the 
motor control and potentially facilitate the individual tailoring of 
STN-DBS modality.
One of the main limitations of our study is represented by 
the small sample size, partially offset by the use of quantitative 
methods of analysis. Moreover, the low number of patients does 
not allow the identification of predictive factors for the presence 
of a dominant STN.
Further studies are needed to identify through functional 
or imaging techniques the presence of a dominant STN before 
surgery.
In conclusion, although caution must be taken given the low 
number of tested subjects, our results seemed to demonstrate 
the presence of a dominant STN in more than 50% of our 
sample of PD patients bilaterally implanted for STN-DBS. In 
these patients, the unilateral stimulation of the dominant STN 
was capable to determine a clinical improvement, measured 
with UPDRS score, similar to what observed with bilateral STN 
stimulation. Importantly, the use of more sophisticated meth-
ods such as multifactorial quantitative gait analysis, suggested 
a role of the dominant STN also on axial symptoms involved 
in walking function, whose disturbances play a relevant role in 
determining disability and changes in quality of life (26, 28) of 
PD patients. If it was possible to identify the PD patients with 
a dominant STN before surgery, it could be indicated for them 
an unilateral implant, to minimize the surgical risks, to reduce 
the side effects due to bilateral DBS and the duration and costs 
of the procedure.
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